Sprycel, also known as dasatinib, is an oral prescription drug used to treat certain types of leukemia and lymphoma. It was developed and marketed by Bristol-Myers Squibb for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
How does Sprycel work?
Sprycel works by blocking two proteins called Bcr-Abl and Src kinase that help cancer cells grow and survive. Normally, these proteins help control cell growth, but in CML patients a genetic change involving chromosomes 9 and 22 makes an abnormal fused gene called Bcr-Abl. This gene causes uncontrolled cell growth by continuously activating the Bcr-Abl and Src proteins. Sprycel inhibits these proteins and stops them from stimulating further cell growth, thereby inducing cell death in cancer cells. It selectively targets leukemia cells and spares normal cells.
Clinical trials evaluating efficacy of Sprycel
Sprycel received US FDA approval in 2001 based on results from several phase 1 and phase 2 clinical trials involving over 400 CML and Ph+ ALL patients who were resistant or intolerant to other tyrosine kinase inhibitor therapies such as Gleevec.
In one key phase 2 trial involving 70 CML patients in accelerated or blast phase, Sprycel induced complete hematologic responses in 93% of patients and partial or complete cytogenetic responses in 51%. It also significantly decreased Bcr-Abl levels. The median duration of response was 12.9 months and median survival was 16.5 months.
Another phase 1/2 trial showed 31% of 32 Ph+ ALL patients achieved complete hematologic response with Sprycel. Cytogenetic responses ranged from 19-41% with a median duration of response between 4.6-13.8 months. Toxicities were generally mild to moderate and manageable.
Large phase 3 clinical trials later demonstrated Sprycel’s superiority over other drugs for initial CML treatment or after resistance to Gleevec. In one trial, Sprycel was better than high-dose imatinib in accelerating molecular responses for newly diagnosed chronic phase CML patients. It also showed improved efficacy in the resistant or intolerant CML and ALL settings compared to other available therapies.
Current indications and recommendations for Sprycel use
Based on its favorable risk-benefit profile demonstrated in clinical trials, the current FDA-approved indications for Sprycel include:
– Newly diagnosed chronic phase CML in adults
– Accelerated phase or blast crisis or chronic phase CML in adults after failure of prior therapy including Gleevec
– Philadelphia chromosome positive ALL in adults after failure of two or more prior therapies.
National Comprehensive Cancer Network (NCCN) guidelines also recommend Sprycel for:
– Patients with chronic phase CML developing resistance to Gleevec
– First-line therapy for patients with chronic phase CML unable to tolerate Gleevec
– As a subsequent therapy after failure of one or two TKI drugs
Side effects and safety considerations of Sprycel
Like other tyrosine kinase inhibitors, Sprycel too can cause certain mild to moderate side effects such as nausea, diarrhea, headache, cough, fatigue, skin rashes etc. However, grade 3/4 thrombocytopenia and neutropenia requiring treatment interruption/dose reduction are more common with Sprycel. Cardiovascular events have also been reported.
Long term follow up studies indicate risk of potential side effects on liver function, pancreatitis and heart conditions with Sprycel use. Close monitoring of blood counts and liver/pancreas function is required during therapy. Sprycel may interact with several other drugs metabolized by the CYP3A4 liver enzyme system. Overall, its toxicity profile is considered acceptable for cancer patients when used appropriately.
Conclusion
In conclusion, Sprycel is a promising oral targeted therapy that successfully competes with first generation kinase inhibitors for treatment of CML and Ph+ ALL. Its ability to induce deeper and sustained molecular responses in newly diagnosed as well as resistant CML patients makes it an important option for managing this genetically driven leukemia. Continued clinical research aims to further optimize Sprycel’s use by addressing challenges related to drug resistance and treatment sequencing.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it